Supported by independent educational grants from Medtronic, sanofi-aventis, and Boehringer Ingelheim Pharmaceuticals, Inc.
Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference.
Kirchhof P, Lip GY, Van Gelder IC, et al. Thromb Haemost. 2011;106:1012-1019.
Rodriguez Y, Garisto JD, Carrillo RG. Circ Arrhythm Electrophysiol. 2011;4:719-723.
Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: results from the AVAIL Registry.
Lopes RD, Shah BR, Olson DM. et al. Stroke. 2011;42:3477-3483.
Woollard M, Poposki J, McWhinnie B, Rawlins L, et al. Emerg Med J. 2011. [Epub ahead of print]
Mabo P, Victor F, Bazin P, Ahres S, et al. Eur Heart J. 2011. [Epub ahead of print]
Incidence, predictive factors, and prognostic value of new-onset atrial fibrillation following transcatheter aortic valve implantation.
Amat-Santos IJ, Rodés-Cabau J, Urena M, et al. J Am Coll Cardiol. 2012;59:178-188.
Procedural complications, rehospitalizations, and repeat procedures after catheter ablation for atrial fibrillation.
Shah RU, Freeman JV, Shilane D, et al. J Am Coll Cardiol. 2012;59:143-149.
Prevalence of asymptomatic and electrically undetectable intracardiac inside-out abrasion in silicon-coated Riata® and Riata® ST implantable cardioverter-defibrillator leads.
Schmutz M, Delacrétaz E, Schwick N, et al. Int J Cardiol. 2012. [Epub ahead of print]
Sex differences in implantable cardioverter-defibrillator outcomes: findings from a prospective defibrillator database.
Macfadden DR, Crystal E, Krahn AD, et al. Ann Intern Med. 2012;156:195-203.
Riata implantable cardioverter-defibrillator lead failure: Analysis of explanted leads with a unique insulation defect.
Hauser RG, McGriff D, Retel LK. Heart Rhythm. 2011. [Epub ahead of print]